AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a Phase IIIb study to evaluate the safety of using Durvalumab in combination with platinum-based chemotherapy, followed by Durvalumab with Olaparib, as a first-line treatment for patients with advanced or recurrent endometrial cancer in Spain. This study, involving approximately 85 patients across 20 sites, aims to assess the safety profile of this treatment regimen.
The study tests two interventions: Durvalumab combined with chemotherapy (carboplatin and paclitaxel) and Durvalumab combined with Olaparib. These treatments are intended to provide a first-line therapeutic option for patients with pMMR advanced or recurrent endometrial cancer.
This interventional study is designed as a single-group, multicenter trial without masking, focusing on treatment as its primary purpose. The study is not recruiting new participants, indicating it is in the active phase of research.
The study began on December 30, 2024, with an estimated completion timeline of 48 months, including a 12-month recruitment period and 36 months of treatment and follow-up. The latest update was submitted on July 18, 2025.
For investors, this study could influence AstraZeneca’s stock performance by potentially expanding its oncology portfolio and enhancing its competitive position in the cancer treatment market. Successful outcomes might boost investor confidence and market valuation.
The study is ongoing, with further details available on the ClinicalTrials portal.